Licensing application submitted to European Medicines Agency for amivantamab as treatment of metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations following disease progression on platinum-based chemotherapy (PBC)

Submission for this EGFR-targeting bispecific antibody is based on data from phase I CHRYSALIS study of use as monotherapy and in combination with lazertinib (3rd generation EGFR TKI) which showed overall response rate of 36%, and 41% in 29 patients previously treated with PBC.

Source:

PharmaTimes